Cell-free DNA Analysis in Cancer
Authors:
- 31 January 2019
- journal article
- letter
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 380 (5) , 501-502
Abstract
Corcoran and Chabner (Nov. 1 issue)1 elegantly describe the use of circulating tumor DNA (ctDNA) analysis in patients with cancer. However, one issue that was not adequately discussed is early detection. We recently analyzed the tumor size, amount of ctDNA in a 10-ml blood sample, fraction of ctDNA in overall cell-free DNA (cfDNA), number of retrieved genomes, and likelihood of tumor detection with ctDNA analysis. We concluded that, in general, this form of technology is unlikely to detect tumors that are smaller than 10 mm in diameter,2 primarily because no retrieval of ctDNA from the circulation in patients with early disease leads to sampling error. Our calculations are supported by recent data showing poor sensitivity (10%) of ctDNA analysis in detecting breast cancer in asymptomatic persons in whom breast cancer has been detected by means of screening mammography.3 Although this new cancer biomarker has exciting potential for many clinical applications, its use for early detection and population screening should be approached with caution.Keywords
This publication has 8 references indexed in Scilit:
- Sensitive tumour detection and classification using plasma cell-free DNA methylomesNature, 2018
- Application of Cell-free DNA Analysis to Cancer TreatmentNew England Journal of Medicine, 2018
- Utility of circulating tumor DNA in cancer diagnostics with emphasis on early detectionBMC Medicine, 2018
- Breast cancer cell-free DNA (cfDNA) profiles reflect underlying tumor biology: The Circulating Cell-Free Genome Atlas (CCGA) study.Journal of Clinical Oncology, 2018
- Detection and localization of surgically resectable cancers with a multi-analyte blood testScience, 2018
- Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA ProfilingCancer Discovery, 2017
- Analysis of Plasma Epstein–Barr Virus DNA to Screen for Nasopharyngeal CancerNew England Journal of Medicine, 2017
- Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancerScience Translational Medicine, 2016